BC 9M 2023 revenue $86.3M, net income $18.8M; Gyre Therapeutics files financials for acquired entity

GYRE THERAPEUTICS, INC.

BC revenue $86.3M for 9M 2023 vs $77.4M in 9M 2022 (+11.5%); net income $18.8M vs $2.3M.
Operating income $25.0M in 9M 2023, up from $7.2M in prior year period.
Cash and CDs total $46.9M as of Sep 30, 2023; equity $83.8M.
Business combination closed Oct 30, 2023; filing provides required historical financials of BC.
Pro forma combined financials also filed as Exhibit 99.2.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.